Chemistry:Trideca-7,9,11-trienoic acid
| |
| |
| Names | |
|---|---|
| IUPAC name
(7E,9E,11E)-Trideca-7,9,11-trienoic acid
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| |
| |
| Properties | |
| C13H20O2 | |
| Molar mass | 208.301 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Trideca-7,9,11-trienoic acid, or (7E,9E,11E)-trideca-7,9,11-trienoic acid, is an polyunsaturated fatty acid. It is present in Aethusa cynapium.[1][2][3]
Pharmacology
Trideca-7,9,11-trienoic acid has been shown to have an antianxiety effect in Mus musculus, Rattus norvegicus, and Homo sapiens. It reduces hypolocomotion caused by anxiety, which was psychopharmacologically induced with mCPP, in Mus musculus and Rattus norvegicus. A 2 mg/kg dose of diazepam has a very similar effect to 20 mg/kg of trideca-7,9,11-trienoic acid. This may suggest that trideca-7,9,11-trienoic acid is also a GABA agonist like diazepam.[1][4][5][6]
Extraction from A. cynapium
Trideca-7,9,11-trienoic acid can be extracted from dried aerial parts of A. cynapium with methanol, followed by chloroform, followed by column chromatography with DCM and methanol (40:60), followed by flash chromatography with DCM and methanol (92.5:7.5), followed by preparative TLC.[1]
Uses
In addition to its potential as an anxiolytic, trideca-7,9,11-trienoic acid has also been studied for use in inks and protective coatings.[1][7]
References
- ↑ 1.0 1.1 1.2 1.3 Shri, Richa; Bhutani, K.K.; Sharma, Anupam (2010). "A new anxiolytic fatty acid from Aethusa cynapium". Fitoterapia 81 (5): 337–340. doi:10.1016/j.fitote.2010.05.003. PMID 20472038. (https://www.academia.edu/4694323/A_new_anxiolytic_fatty_acid_from_Aethusa_cynapium)
- ↑ "(7E,9E,11E)-trideca-7,9,11-trienoic acid". PubChem. National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/compound/88499374. 3.1.2025.
- ↑ Gerald Sugarman, Michael W. O'Neill, "Composition for ink vehicles and protective coatings", patent EP0503897A1 16.9.1992.
- ↑ Bilkei-Gorzo A, Gyertyar I, Szabados T (1996). "mCPP-induced anxiety—a potential new method for screening anxiolytic activity". Neurobiology 4: 253–5.
- ↑ Bilkei-Gorzo A, Gyertyar I, Levay G (1998). "mCPP-induced anxiety in the light–dark box in rats—a new method for screening anxiolytic activity". Psychopharmacology 136 (3): 291–8. doi:10.1007/s002130050568. PMID 9566815.
- ↑ "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics". Acta Neurologica Scandinavica 118 (2): 69–86. August 2008. doi:10.1111/j.1600-0404.2008.01004.x. PMID 18384456.
- ↑ Composition for ink vehicles and protective coatings, European Patent Office, EP0503897A1, Gerald SugarmanMichael W. O'neill, 16.9.1992. (https://patents.google.com/patent/EP0503897A1)
 |  |
